Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema for hypertension associated with obesity
jRCT2031260647Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised trial of CagriSema, semaglutide and cagrilintide in hypertension (HTN) and obesity (4 arms), sponsored by Novo Nordisk. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
hypertension (HTN)obesity
Beyond the preview
Go deeper on jRCT2031260647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260647.